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Letters tO the EditOr
Rare and Novel 
Epidermal Growth 
Factor Receptor 
Mutations in Non–
Small-Cell Lung 
Cancer and Lack of 
Clinical Response to 
Gefitinib in Two Cases
To the Editor:
Small-molecule epidermal growth 
factor receptor tyrosine kinase inhibi-
tors (EGFR-TKI) such as gefitinib and 
erlotinib frequently induce durable 
responses in patients whose pulmo-
nary adenocarcinoma contains gain- 
of-function mutations of the EGFR 
kinase domain, which is encoded by 
exons 18 to 21. The classical responsive 
mutations are deletions in exon 19, and 
L858R in exon 21.1 Nevertheless, some 
mutations such as the gatekeeper muta-
tion, T790M, and insertions (or in-frame 
duplications) in exon 20 confer resis-
tance to EGFR-TKI therapy.2 A recent 
article in this journal describes clinical 
correlations of rare missense muta-
tions of the EGFR gene, which were 
defined as mutations in exons 18 and 
20, uncommon mutations in exons 19 
and 21, and/or the presence of different 
mutations in a single tumor (complex 
mutations).3 The clinical significance of 
rare mutations is often uncertain unlike 
that of the classical responsive and resis-
tance mutations of EGFR. This work3 
extends the findings of another recent 
report4 of the effectiveness of EGFR-
TKI on “uncommon” EGFR mutations 
of unknown clinical significance in 
non–small-cell lung cancer. Here, we 
add to this experience by reporting two 
patients whose lung cancers had EGFR 
missense mutations associated with the 
lack of a clinical response to gefitinib 
therapy.
PATIENT 1 (P1)
A 59-year-old Indian-born male 
never-smoker presented with chest pain. 
Computed tomography (CT) revealed 
a destructive right 4th rib lesion and a 
22 mm right middle lobe lung lesion, 
which cytology showed to be large-cell 
carcinoma. He received four cycles of 
cisplatin/pemetrexed, and achieved a 
partial response by Response Evaluation 
Criteria in Solid Tumors (RECIST) 1.1. 
Radiologic progression was observed 
9 weeks later. EGFR mutation analy-
sis revealed a missense mutation 
(c.2590G>A[p.Ala864Thr]) in exon 21. 
He received second-line gefitinib 250 
mg daily but developed rapidly pro-
gressive disease with malignant ascites, 
peritoneal masses, and paravertebral 
and psoas muscle metastases. His best 
response by RECIST 1.1 was progres-
sive disease and his progression-free 
survival interval was 1 month. He died 
1 week after ceasing gefitinib.
PATIENT 2 (P2)
A 71-year-old Iranian-born woman 
never-smoker presented with a 2.7 cm 
right upper lobe lung nodule. At wedge 
resection, a TTF1+ pulmonary adenocar-
cinoma (T1bN0M0R0) was diagnosed. 
Seven months later, she developed 
metastases with new right lung nodules, 
lymphangitis carcinomatosis, and a 
biopsy-proven wound recurrence show-
ing two somatic EGFR missense muta-
tions, c.2096C>T(p.Pro699Leu) in exon 
18 and c.2410G>A(p.Glu804Lys) in 
exon 20. She received first-line gefitinib 
250 mg daily but developed worsening 
dyspnoea. Her chest CT scan showed 
worsening of changes of lymphangitis 
carcinomatosis, which was considered 
evidence of disease progression by 
RECIST 1.1. Her progression-free sur-
vival interval was 1 month, and she died 
6 weeks after ceasing gefitinib.
In each of these cases, exons 18 
to 21 of the EGFR gene were directly 
sequenced by the Sanger method in 
both forward and reverse directions 
to confirm the presence of the newly 
described mutations and the absence of 
other EGFR mutations including classi-
cal EGFR mutations. Neither case had a 
V600E BRAF mutation. A KRAS muta-
tion (c.35G>T[p.G12V]) was detected 
in P1’s tumor only.
The EGFR mutations reported 
here may be defined as rare3 because 
P1’s mutation in EGFR exon 19 has 
only been reported once in the Catalog 
of Somatic Mutations in Cancer 
(CoSMIC) database (www.sanger.ac.uk/ 
genetics/CGP/cosmic/), and P2’s tumor 
carried a novel complex mutation affect-
ing exons 18 and 20 of the EGFR gene.
The A864T mutation (found 
in EGFR exon 21 of P1’s tumor) was 
associated with constitutive activity of 
EGFR in vitro and partial gefitinib sen-
sitivity (IC
50
 value of 75 nM).5 Although 
the A864T mutation was not evidently 
associated with EGFR-TKI resistance,6 
P1’s concurrent KRAS mutation may 
have been responsible for primary resis-
tance in his case.7 To our knowledge, 
the P699L mutation in exon 18 of P2’s 
tumor has not previously been reported. 
The other mutation of P2’s complex, 
E804K in exon 20, has been reported.4 
In this case, the 53-year-old female 
never-smoker had stage IV pulmonary 
adenocarcinoma with a complex muta-
tion: E804K and a classic gefitinib-re-
sponsive deletion mutation in exon 19. 
That this patient had a partial response 
to gefitinib together with a progression-
free survival of 14.3 months4 suggests 
that E804K did not confer resistance 
mutation to gefitinib. Therefore, we sug-
gest that the P699L mutation itself may 
have engendered resistance to gefitinib 
in P2.
In our two cases, the natural his-
tory of EGFR mutation-positive non–
small-cell lung cancer indicates a lack 
of response to gefitinib therapy, and 
warrants further investigation of the 
molecular mechanisms underlying this 
apparent drug resistance.
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Significant Response 
to Gemcitabine 
Monotherapy in 
Primary Pleural 
Epithelioid 
Angiosarcoma
To the Editor:
Systemic chemotherapy is one 
treatment option for advanced epithe-
lioid angiosarcoma, but no standard reg-
imen has yet been established because 
of the rarity of the disease. We report a 
case of advanced epithelioid angiosar-
coma showing marked response with 
gemcitabine monotherapy.
A 72-year-old man presented 
with a 1-month history of dyspnea 
on exertion. Computed tomography 
revealed a left pleural tumor measur-
ing 6.5 cm and bilateral pleural effu-
sions. Histopathological examination of 
the pleural tumor obtained by biopsies 
under echographic guidance revealed 
neoplastic proliferation characterized 
by nests of highly atypical, large, and 
round to spindle-shaped epithelioid 
cells with abundant eosinophilic cyto-
plasm and hyperchromatic nuclei con-
taining prominent nucleoli. Atypical 
epithelioid cells showed focal areas of 
vascular formation and intracellular 
lumina containing erythrocytes, and 
positive staining for CD31, a vascular 
marker. Advanced epithelioid angiosar-
coma with bilateral malignant pleural 
effusions was diagnosed, and systemic 
chemotherapy was initiated.
Despite treatment using four 
cycles of combination chemotherapy 
with ifosfamide and adriamycin, new 
evidence suggested skin and pulmonary 
metastases. After two cycles of second-
line chemotherapy with carboplatin 
and etoposide, skin lesions enlarged. 
Paclitaxel monotherapy (80 mg/m2 on 
days 1, 8, and 15 every 28 days) was 
administered as a third-line option, but 
cutaneous involvement progressed. As 
the patient suffered from severe cancer 
pain and bleeding from skin metasta-
ses after paclitaxel monotherapy, he 
received oral S-1 with concurrent pal-
liative radiotherapy to the skin lesions, 
which also proved insufficient. Skin 
metastases progressed rapidly (Figs. 1 
and 2A), and the patient underwent fifth-
line chemotherapy with gemcitabine 
(1000 mg/m2 on days 1 and 8, every 
21 days). After six cycles of gemcit-
abine monotherapy, computed tomog-
raphy revealed excellent response with 
marked reduction of skin lesions (Fig. 
2B). As cancer pain and bleeding were 
markedly improved, the patient contin-
ued gemcitabine monotherapy for nine 
cycles over 30 weeks, with good quality 
of life. The patient died 2 years after ini-
tial diagnosis because of serious hem-
orrhage from the tumor.
Epithelioid angiosarcomas are a 
subtype of soft-tissue sarcoma (STS) 
and are extremely rare aggressive 
malignancies of endothelial origin.1 The 
prognosis of unresectable angiosarcoma 
is typically poor. Penel et al.2 reported 
a median time to progression of 4 
months, with median overall survival 
of 8 months. Patients with angiosar-
coma display symptoms attributable 
to a hypocoagulable state.3 The pres-
ent patient suffered bleeding from skin 
metastases. For advanced-stage disease, 
systemic chemotherapy is considered 
a treatment option. As a monotherapy, 
paclitaxel has shown effectiveness 
against advanced-stage angiosarcoma.2 
Gemcitabine has been reported as inac-
tive against advanced STS, providing a 
response rate of only 3.23%.4 However, 
Stacchiotti et al.5 recently reported 
the overall response rate of advanced 
angiosarcoma to gemcitabine was 68%, 
with acceptable levels of toxicity. This 
suggests that gemcitabine could rep-
resent a good option for unresectable 
angiosarcoma, if not other subtypes of 
STS. Although paclitaxel was ineffec-
tive in our case, gemcitabine led to good 
response with noted reduction of the skin 
mass. The patient’s overall condition 
also improved markedly. The favorable 
clinical outcome in this case suggests 
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